Cargando…
Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
Autores principales: | Krown, Susan E, Fingleton, Barbara, Lee, Jeannette Y, Egorin, Merrill J, Koon, Henry B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002724/ http://dx.doi.org/10.1186/1750-9378-5-S1-A62 |
Ejemplares similares
-
Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS)
por: Koon, Henry B, et al.
Publicado: (2010) -
Four year survival in untreated AIDS related-Kaposi sarcoma (AIDS-KS) in Jos, Nigeria
por: Agaba, P, et al.
Publicado: (2009) -
Cancers associated with Kaposi's sarcoma (KS) in AIDS: a link between KS herpesvirus and immunoblastic lymphoma
por: Engels, E A, et al.
Publicado: (2001) -
Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
por: Barta, Stefan K, et al.
Publicado: (2010) -
Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study
por: Haigentz, Missak, et al.
Publicado: (2022)